Augmentin

Augmentin is a brand name for the combination medication containing amoxicillin and clavulanic acid. It is a broad-spectrum antibiotic used to treat various bacterial infections. Here is some information about Augmentin:

Treatment of Bacterial Infections

Augmentin (amoxicillin/clavulanic acid) is commonly prescribed for the treatment of bacterial infections, including respiratory tract infections (such as sinusitis, bronchitis, and pneumonia), urinary tract infections, skin and soft tissue infections, and certain types of ear infections. It works by killing or inhibiting the growth of bacteria causing the infection.

Combination of Amoxicillin and Clavulanic Acid

Augmentin contains two active ingredients: amoxicillin, which is a penicillin-type antibiotic that fights bacterial infections, and clavulanic acid, which helps to protect amoxicillin from being destroyed by certain enzymes produced by bacteria. This combination enhances the effectiveness of the medication against a broader range of bacteria.

Dosage and Administration

The dosage of Augmentin will depend on the specific infection being treated, its severity, and the age and weight of the individual. It is available in various forms, including tablets, extended-release tablets, and oral suspension. The medication should be taken as directed by a healthcare professional, and it is important to follow the recommended dosage and administration instructions.

Potential Side Effects and Precautions

Common side effects of Augmentin may include diarrhea, nausea, vomiting, rash, and allergic reactions. It is important to complete the full course of treatment as prescribed, even if the symptoms improve, to ensure effective eradication of the infection.

Augmentin should not be taken by individuals who have a history of allergic reactions to penicillin or other beta-lactam antibiotics. It may interact with other medications, so it is important to inform your healthcare professional about all the medications you are currently taking.

Consultation with Healthcare Professional

Augmentin is a prescription medication, and its use should be supervised by a healthcare professional. It is important to consult with a doctor to evaluate the specific infection, determine the appropriate treatment plan, and discuss the usage and potential side effects of Augmentin.

WARNING: Please consult with a healthcare professional or doctor for personalized advice and guidance regarding the use of Augmentin or any other antibiotic medication for the treatment of bacterial infections. They will be able to provide specific instructions based on your medical history and individual needs.

References

1. ^ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 97. ISBN 9781284057560.
2. ^ Jump up to:^a b c d World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 102. hdl:10665/44053. ISBN 9789241547659.
3. ^ “Regulatory Decision Summary – Amoxicillin Sodium And Potassium Clavulanate For Injection”. Health Canada. 23 October 2014. Retrieved 4 June 2022.
4. ^ Jump up to:^{a b c d e f g h} “Amoxicillin and Clavulanate Potassium”. The American Society of Health-System Pharmacists. Archived from the original on 29 November 2016. Retrieved 8 December 2016.
5. ^ Gillies M, Ranakusuma A, Hoffmann T, Thorning S, McGuire T, Glasziou P, Del Mar C (January 2015). “Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication”. CMAJ. 187 (1): E21–E31. doi:10.1503/cmaj.140848. PMC 4284189. PMID 25404399.
6. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
7. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
8. ^ World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl:10665/312266. ISBN 9789241515528.
9. ^ “The Top 300 of 2020”. ClinCalc. Retrieved 7 October 2022.
10. ^ “Amoxicillin; Clavulanate – Drug Usage Statistics”. ClinCalc. Retrieved 7 October 2022.
11. ^ Jump up to:^a b c d British National Formulary (57th ed.). March 2009.
12. ^ Jump up to:^a b c d Gordon D (2010). “Amoxicillin–Clavulanic Acid (Co-Amoxiclav)”. In Grayson ML; et al. (eds.). Kucers’ the Use of Antibiotics: a Clinical Review of Antibacterial, Antifungal, Antiparasitic and Antiviral Drugs. London: Hodder Arnold/ASM Press. pp. 193–4. ISBN 978-0-340-92767-0.
13. ^ World Health Organization (2016). WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. World Health Organization. hdl:10665/250125. ISBN 9789241549639.
14. ^ Mishra G, Caminero J (2018). “First Successful Use of Low Dose Amoxicillin-Clavulanic Acid in Management of Drug Resistant Tuberculosis”. Journal of Clinical and Diagnostic Research. 12 (10): OD08–OD10. doi:10.7860/JCDR/2018/37279.12145. Retrieved 7 May 2021.
15. ^ Harr T, French LE (December 2010). “Toxic epidermal necrolysis and Stevens-Johnson syndrome”. Orphanet Journal of Rare Diseases. 5: 39. doi:10.1186/1750-1172-5-39. PMC 3018455. PMID 21162721.
16. ^ GB 2005538, Crowley PJ, “Pharmaceutical compositsions”, published 1982-05-26, assigned to Beecham Group Ltd.
17. ^ Bryan J (23 June 2011). “Still going strong at 30: co-amoxiclav”. The Pharmaceutical Journal. 286: 762.
18. ^ “Augmentin — Prescribing Information” (PDF). December 2006. Archived (PDF) from the original on 20 December 2013.
19. ^ Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE (October 1988). “Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin”. British Journal of Clinical Pharmacology. 26 (4): 385–390. doi:10.1111/j.1365-2125.1988.tb03395.x. PMC 1386558. PMID 3190988.
20. ^ “Canine Infectious Tracheobronchitis (Kennel Cough)”. Archived from the original on 21 May 2006. Retrieved 30 May 2013.
21. ^ “Kennel Cough – Symptoms and Treatment”. 30 April 2013. Archived from the original on 10 May 2013. Retrieved 30 May 2013.
22. ^ Federation of Veterinarians in Europe Position Paper: “Antibiotic Resistance & Prudent Use of Antibiotics in Veterinary Medicine”